Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $10.7950 (-4.47%) ($10.7950 - $10.7950) on Thu. Feb. 17, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.61% (three month average) | RSI | 61 | Latest Price | $10.7950(-4.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(77%) ARKG(72%) IBB(69%) ARKK(66%) IBUY(62%) | Factors Impacting TGTX price | TGTX will decline at least -4.305% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-25%) TBT(-11%) USO(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.305% (StdDev 8.61%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $11.19 | 5 Day Moving Average | $10.68(1.08%) | 10 Day Moving Average | $10.57(2.13%) | 20 Day Moving Average | $11.19(-3.53%) | To recent high | -60.4% | To recent low | 27.4% | Market Cap | $1.367b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |